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Abstract 
Background: Prevention and early detection of colorectal cancer (CRC) is a global priority, with many countries 
conducting population‑based CRC screening programs. Although colonoscopy is the most accurate diagnostic 
method for early CRC detection, adherence remains low because of its invasiveness and the need for extensive bowel 
preparation. Non‑invasive fecal occult blood tests or fecal immunochemical tests are available; however, their sensitiv‑
ity is relatively low. Syndecan‑2 (SDC2) is a stool‑based DNA methylation marker used for early detection of CRC. Using 
the EarlyTect™‑Colon Cancer test, the sensitivity and specificity of SDC2 methylation in stool DNA for detecting CRC 
were previously demonstrated to be greater than 90%. Therefore, a larger trial to validate its use for CRC screening in 
asymptomatic populations is now required.
Methods: All participants will collect their stool (at least 20 g) before undergoing screening colonoscopy. The 
samples will be sent to a central laboratory for analysis. Stool DNA will be isolated using a GT Stool DNA Extraction kit, 
according to the manufacturer’s protocol. Before performing the methylation test, stool DNA (2 µg per reaction) will 
be treated with bisulfite, according to manufacturer’s instructions. SDC2 and COL2A1 control reactions will be per‑
formed in a single tube. The SDC2 methylation test will be performed using an AB 7500 Fast Real‑time PCR system.  CT 
values will be calculated using the 7500 software accompanying the instrument. Results from the EarlyTect™‑Colon 
Cancer test will be compared against those obtained from colonoscopy and any corresponding diagnostic histopa‑
thology from clinically significant biopsied or subsequently excised lesions. Based on these results, participants will be 
divided into three groups: CRC, polyp, and negative. The following clinical data will be recorded for the participants: 
sex, age, colonoscopy results, and clinical stage (for CRC cases).
Discussion: This trial investigates the clinical performance of a device that allows quantitative detection of a sin‑
gle DNA marker, SDC2 methylation, in human stool DNA in asymptomatic populations. The results of this trial are 
expected to be beneficial for CRC screening and may help make colonoscopy a selective procedure used only in 
populations with a high risk of CRC.
Trial registration: This trial (NCT04304131) was registered at ClinicalTrials.gov on March 11, 2020 and is available at 
https:// clini caltr ials. gov/ ct2/ show/ NCT04 304131? cond= NCT04 30413 1& draw= 2& rank=1.
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Background
Colorectal cancer (CRC) is the second leading cause of 
cancer-related death worldwide [1]. Studies estimate 
that more than 250,000 new cases of CRC and approxi-
mately 9000 CRC-related deaths will occur in 2020 
in South Korea [2]. The mean 5-year survival rate for 
early-stage CRC can be as high as 90% but can be less 
than 10% if metastasis occurs [3]. Therefore, prevention 
and early detection of CRC has emerged as a significant 
global initiative, and many countries conduct popu-
lation-based CRC screening programs [4]. Although 
colonoscopy is the most accurate diagnostic method 
for early CRC detection, adherence remains very low 
due to the invasiveness of the procedure and the need 
for extensive bowel preparation [5, 6]. Sigmoidoscopy 
without bowel preparation can be used instead of colo-
noscopy, but it fails to detect abnormalities between the 
cecum and sigmoid colon. Digital rectal examination is 
the easiest diagnostic method, but it is only useful for 
detecting rectal cancer. Although computed tomogra-
phy (CT) colonography is a non-invasive method that 
can visualize the proximal colon above the obstruct-
ing lesion in extraluminal views, it is not as accurate as 
colonoscopy [7]. Noninvasive fecal occult blood tests 
and fecal immunochemical tests (FITs) are also availa-
ble; however, their sensitivity is relatively low [8]. As an 
alternative to overcome these limitations, noninvasive, 
simple, and accurate molecular diagnostic tests using 
bodily fluids or feces have been gaining attention. These 
tests may be used for screening in patients reluctant 
to undergo screening colonoscopies, thereby allow-
ing colonoscopy to be selectively performed in specific 
cases to detect early-stage CRC.
CRC arises from an accumulation of genetic and 
epigenetic abnormalities in the genome [9], includ-
ing DNA methylation, in which methyl  (CH3) groups 
are added to the 5′ position of cytosine (C) in the CpG 
island of a DNA molecule. Aberrant DNA methylation 
is associated with tumorigenesis of all types of can-
cer and has been established as one of the most com-
mon molecular alterations in CRC [10–12]. Therefore, 
specific DNA sites that are aberrantly methylated in 
colorectal neoplasms are well recognized as poten-
tial non-invasive molecular biomarkers for early CRC 
detection.
Regulatory regions in most genes consist of a 
sequence dense with CpG islands. If methylation 
occurs at the gene regulatory region, structural changes 
in chromatin, including in the CpG island, are induced, 
resulting in gene silencing [13]. Aberrant DNA meth-
ylation often occurs prior to genetic alterations. Thus, 
abnormal DNA methylation of certain genes may occur 
in progressive cancer, as well as in precancerous lesions 
(e.g., adenomatous polyps). Therefore, the presence of 
methylation of specific genes could be used as a bio-
marker for the diagnosis of early-stage cancer [14]. Tar-
geting cancer-specific methylated DNA for early cancer 
detection has many advantages, when compared with 
other known biomarkers [15].
In cancer tissues, abnormally methylated DNA sites 
are often shed into the blood and circulate in the form 
of cell-free DNA. In addition, exfoliated cells from the 
colonic mucosa are frequently present in feces. Because 
stool specimens from CRC patients usually contain 
exfoliated tumor cells, stool-derived DNA testing has 
emerged as a new strategy for the non-invasive detec-
tion of CRC and its precursor lesions [16]. We previ-
ously identified syndecan-2 (SDC2) as a potential 
stool-based DNA methylation marker for early CRC 
detection [17, 18]. Moreover, we reported that detect-
ing SDC2 methylation has greater than 90% sensitiv-
ity and specificity, suggesting that this strategy would 
be an excellent non-invasive screening test for early 
diagnosis of CRC [19]. Here, we report the protocol of 
a larger trial to validate the use of SDC2 methylation 




This study is a prospective, multicenter trial to evaluate 
the clinical performance of a device (EarlyTect™-Colon 
Cancer, Genomictree, Daejeon, Korea) that allows for 
the quantitative detection of a single DNA marker, 
SDC2 methylation, in human stool DNA from asymp-
tomatic individuals.
Before the study is initiated, the staff will be trained 
in all aspects of the study, including the assay pro-
cedure and instrument use. All eligible participants 
scheduled for colonoscopy for any reason will be 
enrolled in this trial. Before initiating bowel prepara-
tion for colonoscopy, all participants will collect at 
least 20  g of their stool using a plastic collection tube 
(50 mL) that is included in the kit. The following sam-
ples will be considered inappropriate for analysis and 
excluded: diarrhea or loose stool, quantities less than 
20  g, samples collected during bowel preparation, and 
Keywords: Colorectal cancer, DNA methylation, Syndecan‑2, Early detection, Biomarker
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samples submitted over 2 weeks after collection. Sam-
ples collected by the participant for the EarlyTect™-
Colon Cancer test will be sent to a central laboratory.
Stool DNA will be isolated using a GT Stool DNA 
Extraction kit (Genomictree, Inc, Daejeon, Korea) 
according to the following instructions:
1. All stool samples will be weighed and thoroughly 
homogenized in the preservative buffer using a mul-
tiple vortexer (Thermo Fisher Scientific, Waltham, 
MA, USA). After homogenization, 2–4 g equivalent 
of each stool sample will be collected and centrifuged 
at 2,000  rpm for 2  min (HA-1000-3; Hanil Science 
Medical, Daejeon, Korea).
2. The supernatants will be discarded, and the pellet 
will be resuspended in 5.0 mL lysis buffer 1 (Genom-
ictree, Inc, Daejeon, Korea) before incubating for 
4 min at room temperature.
3. The samples will be centrifuged at 2000  rpm for 
2 min, and the supernatant will be discarded before 
adding 2.0 mL lysis buffer 2 (Genomictree, Inc, Dae-
jeon, Korea) and 30 μL proteinase K (0.4  mg/mL, 
Sigma-Aldrich, St. Louis, MO, USA). The samples 
will then be incubated at 70 °C for 10 min.
4. The samples will be centrifuged at 3000  rpm for 
5 min, and 0.75 mL supernatant will be added to the 
MaXtract High-Density tube (Qiagen, Hilden, Ger-
many). Tris-saturated phenol–chloroform-isoamyla-
lcohol (25:24:1 [v/v]; Sigma-Aldrich, St. Louis, MO, 
USA) will then be added to the samples.
5. The samples will be thoroughly mixed for 1  min 
and then centrifuged in a microcentrifuge at maxi-
mum speed for 10  min. The supernatant (0.5  mL) 
will be transferred to a new tube, and 1/10 volume 
of 3 mol/L sodium acetate (pH 5.2; Welgene, Gyeo-
ngsan, Korea) and an equal volume of isopropanol 
(Merck, Darmstadt, Germany) will be added to the 
sample.
6. Total nucleic acid will then be precipitated by cen-
trifugation at maximum speed for 10 min. The DNA 
pellet will be washed with 1.0  mL 70% ethanol and 
dried. DNA concentration will be measured using 
the Qubit dsDNA BR Assay Kit (Thermo Fisher Sci-
entific, Waltham, MA, USA). A solid phase magnetic 
bead-based stool DNA extraction method will also 
be available.
All information regarding the stool sample will be 
anonymized at the time of examination, treated as blind 
(single-blind) to the operator, and randomly assigned a 
unique number. The sample will then be sent to a cen-
tral laboratory to test for SDC2 methylation. After study 
enrollment is complete, the methylation analysis results 
will be disclosed. The results and case report form (CRF) 
will be compared and analyzed to evaluate the sensi-
tivity and specificity of the EarlyTect™-Colon Cancer 
test. Residual stool samples may be archived for further 
research. Clinical data and samples will be maintained 
in a manner that preserves the anonymity of all subjects. 
Specimens will be stored for 5 years in the on-site biore-
pository of the central laboratory for potential use in 
future research. A schematic diagram of the trial work-
flow is depicted in Fig. 1.
The SDC2 methylation test will be performed accord-
ing to the GT-CRC-UM-701 protocol (provided by the 
Sponsor) using the AB 7500 Fast Real-time PCR Sys-
tem (Thermo Fisher Scientific, Waltham, MA, USA). 
Briefly, 2 µg stool-derived genomic DNA will be chemi-
cally modified with sodium bisulfite using the EZ DNA 
Methylation-Gold kit (ZYMO Research, USA), accord-
ing to the manufacturer’s instructions. For PCR analysis, 
SDC2 and COL2A1 control reactions will be performed 
twice in a single tube, as previously described [18, 19]. 
 CT values will be calculated using the software accom-
panying the AB 7500 Fast Real-Time PCR System. SDC2 
methylation will be considered detected if  CT is less than 
40 cycles and not detected if  CT is not measurable [17]. 
To maximize clinical sensitivity, SDC2 methylation will 
be considered positive if at least one of two PCR reac-
tions has detectable methylated SDC2. Thus, samples will 
be categorized as positive if at least one of two reactions 
(1/2 algorithm) has detectable SDC2 and considered 
negative if SDC2 methylation is not measurable in both 
reactions. Our previous clinical study showed that the 
95% limit of detection of the EarlyTect™-Colon Cancer 
Fig. 1 Schematic diagram of the workflow of the trial
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assay was 34.5  pg, corresponding to approximately 20 
diploid genome copies [19]. Reproducibility and repeat-
ability of the assay were acceptable, within a coefficient 
of variation of 5%. A total of 23 potential interfering sub-
stances, selected because of their clinical and dietary uses 
in South Korea, were confirmed to have no effect on the 
test performance of EarlyTect™-Colon Cancer assay. The 
assay also exhibited no cross-reactivity, even when excess 
amounts  (105–106 genome copies) of bacterial and viral 
DNA were tested.
Results from the EarlyTect™-Colon Cancer test will be 
compared against those obtained by colonoscopy and 
any corresponding diagnostic histopathology from clini-
cally significant biopsied or subsequently excised lesions. 
Based on these results, participants will be divided into 
three groups: CRC (group 1), polyp (group 2), and nega-
tive (control). The following clinical data will be recorded 
for the participants: sex, age, colonoscopy results, and 
clinical stage (in the CRC case group).
Participant selection criteria are as follows:
Inclusion Criteria
1. No symptoms suggestive of CRC.
2. The individual provides written informed consent.
3. The individual is at least 60  years old when they 
receive a colonoscopy.
4. Criteria for high-risk CRC patients younger than 
60 years old who will participate in the trial are as fol-
lows:
• At least one parent and/or sibling was diagnosed 
with colorectal cancer before age 55 years.
• One of his/her parents, brothers, and sisters was 
diagnosed with colorectal cancer after age 55 years.
• More than two of his/her parents, brothers, and sis-
ters were diagnosed with colorectal cancer.
• Previous polypectomy for pathologically confirmed 
adenoma (at least 1 year ago).
• Occurrence of inflammatory bowel disease (diag-
nosed at least 15 years ago).
5. The individual provides more than 20  g of his/her 
stool for analysis.
Exclusion Criteria
1. Younger than 60 years and does not meet the afore-
mentioned high-risk criteria.
2. Receiving or has received any type of therapy for 
CRC.
3. Less than 20 g of stool is provided for analysis.
4. Stool is considered inadequate for analysis (e.g., diar-
rhea or loose stool).
Objective
This trial aims to validate the use of SDC2 methylation in 
stool DNA for early detection of CRC in asymptomatic 
populations. The primary endpoint of this study is to 
evaluate the sensitivity and specificity of the EarlyTect™-
Colon Cancer for detecting CRC.
Sample size calculation
Because this is not a randomized controlled trial, a sta-
tistical calculation for comparative analysis was not con-
sidered. Instead, we have assumed that the prevalence 
of colon polyps in Korea is 25% based on our previ-
ous pilot study, in which we found an 80% sensitivity of 
EarlyTect™-Colon Cancer for detecting CRC and polyps 
in 585 patients [19]. Therefore, at least 476 participants 
are needed to identify polyps or cancers. In our previ-
ous study, we intentionally controlled the types of cases 
(i.e., 245 CRC, 44 adenomatous polyps, and 245 negative 
colonoscopy results). However, we will enroll more than 
two times the number of cases (n = 1000) in this trial and 
specifically include asymptomatic participants who will 
undergo colonoscopy. Assuming a drop-out rate of 10%, 
1112 participants will be enrolled in this trial.
Data collection and management
The authors will use an electronic CRF (Excel, Micro-
soft, USA) to record clinical data and information. Prin-
cipal investigators or clinical research coordinators at 
each site will enter clinical data into the CRF. Approved 
researchers from the central data managing institution 
will manage the data and information. Only the princi-
pal investigator will be able to access the final trial data-
set and analyze it. Personal information regarding the 
enrolled participants will remain anonymous for 5 years 
and deleted to protect confidentiality.
Drop‑out
A participant can be removed from the trial for the fol-
lowing reasons:
1. Submission of an unacceptable stool sample
2. Refusal to participate for any reason
Statistical analysis
To calculate sensitivity and specificity, the test results will 
be denoted with dichotomous variables, namely “1” for 
methylation-positive individuals and “0” for methylation-
negative individuals. Sensitivity and specificity for CRC 
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detection, area under the curve (AUC) value, and 95% 
confidence interval (CI) will be calculated using receiver 
operating characteristics (ROC) analysis (SAS v.9.4). The 
cut-off value for  CT will be less than 40, and the following 
endpoints will be assessed:
• True positive (TP): SDC2 methylation-positive in 
CRC patients
• True negative (TN): SDC2 methylation-negative in 
the control (negative) subjects
• False-positive (FP): SDC2 methylation-positive in the 
control subjects
• False-negative (FN): SDC2 methylation-negative in 
CRC patients
• Sensitivity = 100 × TP/(TP + FN)
• Specificity = 100 × TN/(TN + FP)
• Negative predictive value (NPV) = TN/(TN + FN)
• Positive predictive value (PPV) = TP/(TP + FP)
Safety evaluation and reporting of adverse effects
We anticipate no adverse events related to using the 
device in this trial.
Data monitoring
A committee will be organized for trial supervision. All 
members of the committee will be certified according to 
Good Clinical Practices at each institution. The commit-
tee will monitor all processes, including data collection, 
records, and management, as well as advise and request 
the principal investigator to alter plans if needed.
Protocol modification
If necessary, the protocol can be modified following 
agreement between the principal investigator and trial 
participants.
Discussion
Using cancer-specific methylated DNA as a target for the 
early detection of cancer has several advantages, when 
compared with using known biomarkers [15]. (1) Unlike 
mRNA or protein, DNA is not easily degraded outside the 
body and maintains relatively high stability when isolated 
from body fluids for non-invasive diagnosis. (2) DNA can 
be amplified by PCR, which enables effective detection 
of minute quantities of methylated biomarker DNA in 
patient samples. (3) mRNA and protein markers require 
multiplexing to increase their accuracy in cancer diagno-
sis, whereas methylated biomarkers can diagnose cancer 
with a single gene and are not greatly affected by sample 
purity. (4) Biomarker levels can vary based on changes in 
emotional, physiological, or pathological factors that are 
unrelated to cancer; however, DNA methylation is highly 
robust in terms of detection because no such changes 
have been reported in  vivo. (5) DNA methylation has a 
higher specificity for specific cancers than gene muta-
tions, mRNA, or protein markers. (6) Unlike with other 
markers, early detection is possible with DNA methyla-
tion because methylation occurs in pre-cancerous lesions 
or early cancers.
Despite its accuracy, patients who undergo colonos-
copy feel discomfort due to its invasiveness and the need 
for extensive bowel preparation. Therefore, a non-inva-
sive and accurate novel screening technique can help 
make colonoscopy a selective procedure. As mentioned 
above, we previously demonstrated the diagnostic accu-
racy of the EarlyTect™-Colon Cancer test for detecting 
CRC in a case-controlled study [19]. EarlyTect™-Colon 
Cancer test exhibited high analytical sensitivity and spec-
ificity for SDC2 methylation detection, as well as high 
reproducibility [19]. These results provided strong evi-
dence that EarlyTect™-Colon Cancer test is optimized for 
analyzing stool-derived DNA. To further improve clinical 
sensitivity for detecting precancerous lesions, digital PCR 
or next generation sequencing techniques will be helpful 
to detect SDC2 methylation in stool samples.
Our stool DNA-based test employs a single methyla-
tion marker SDC2 for detecting CRC, whereas the mul-
titarget stool-based DNA test called Cologuard (which 
is USA Food and Drug Administration-approved) 
assesses the presence of 2 methylation markers (BMP3 
and NDRG4) and KRAS mutations and includes FIT of 
stool samples. The SDC2 methylation test has the same 
high sensitivity for detecting CRC as Cologuard [20]. 
Furthermore, the NPV of our test is comparable to that 
of Cologuard (99.9%) and FIT (99.7%), indicating that a 
negative methylation test result can provide similar infor-
mation regarding the absence of CRC [18].
It has been reported that aberrant SDC2 methyla-
tion occurs frequently in the early stages of neoplasia, is 
maintained in advanced CRC, and is unaffected by such 
factors as disease stage, age, sex, and race. These findings 
were observed in clinical studies comparing methylation 
of SDC2 in stool DNA from patients with different stages 
of CRC, as well as from healthy subjects [17–19, 21, 22]. 
Several other studies have also reported tests for detect-
ing CRC based on SDC2 methylation in stool DNA [6, 21, 
22]. Overall, these reports showed sensitivities of 77.4–
81.1% and specificities of 88.2–98%, which are compara-
ble to the values of our test.
Nevertheless, trials involving asymptomatic individu-
als are required to confirm whether the EarlyTect™-
Colon Cancer device is a useful cancer-screening tool. 
Enrollment for this trial began on June 7, 2020 after 
registration was opened on ClinicalTrials.gov on March 
11, 2020 (NCT04304131). This is the first prospective, 
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multicenter trial to evaluate the clinical performance of 
EarlyTect™-Colon Cancer test in asymptomatic high-
risk Korean populations. This test uses a real-time PCR 
assay to detect a single novel DNA methylation marker, 
methylated SDC2, in stool DNA. We were the first group 
to identify the usefulness of this biomarker, and we pro-
prietarily developed the EarlyTect™-Colon Cancer test 
for early CRC detection. Some similar clinical trials 
have taken advantage of our discovery and used meth-
ylated SDC2 as a biomarker in stool DNA tests for CRC 
detection; these tests exhibited very good performance, 
as expected. These similar trials utilizing methylated 
SDC2 as a biomarker provide further evidence that SDC2 
methylation analysis is a useful noninvasive diagnostic 
approach for early detection of CRC, which may improve 
current diagnostic practices when used in conjunction 
with existing screening tools, such as FIT and colonos-
copy [6, 21, 22].
We expect that this trial will provide results that will be 
beneficial for healthy people who want to avoid colonos-
copy. Although the EarlyTect™-Colon Cancer test can-
not match colonoscopy in terms of accuracy, it can still 
be used for early detection of CRC. This study protocol 
uses a prospective clinical study design to validate the 
effectiveness of SDC2 methylation, a new biomarker for 
non-invasive early detection of CRC, in a relatively small 
population of high-risk individuals. This work should 
provide practical information for the design of a larger-
scale prospective clinical study of an average-risk popula-
tion to clarify the use of EarlyTect™-Colon Cancer test as 
a screening tool for CRC.
Study status
A total of 231 patients were enrolled at the time of sub-
mission (November 2, 2020).
Abbreviations
CRC : Colorectal cancer; SDC2: Syndecan‑2; CRF: Case report form; TP: True 
positive; TN: True negative; FP: False positive; FN: False negative; FIT: Fecal 
immunochemical test; CT: Computed tomography.
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